TP53 and B-cell chronic lymphocytic leukemia: The study randomized treatment-naïve patients with CLL without del(17p) or TP53 mutation to receive either acalabrutinib plus venetoclax, acalabrutinib plus venetoclax plus obinutuzumab, or chemoimmunotherapy (FCR or bendamustine plus rituximab).